Drug Database
CI

cisplatin powder (Randa / IA CALL)

✓ Approved

Nippon Kayaku Co.,Ltd. · 小分子 · 小分子

什么是 cisplatin powder?

cisplatin powder 是一种小分子,由Nippon Kayaku Co.,Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraarterial Injection。

药物档案

商品名Randa, IA CALL
公司Nippon Kayaku Co.,Ltd.
药物类别小分子
给药途径Injectable (Others), Intraarterial Injection
状态Approved

治疗适应症

cisplatin powder 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatic cancer✓ Approved

相关研究文献

PubMedCell death discovery2026-11-19

Short-chain fatty acids significantly alleviate cisplatin induced sensory cell damage and hearing loss by maintaining the expression of MUTYH.

Zhang Zhen-Xian ZX, Zhu Ya-Qiong YQ, Yan Feng-Xu FX, Wang Jia-Qi JQ et al.

Cisplatin is a potent, broad-spectrum chemotherapeutic agent widely used against multiple malignancies, yet its clinical utility is substantially restricted by dose-limiting adverse effects dominated by nephrotoxicity and ototoxicity. Although cisplatin-induced ototoxicity has been recognized for decades, the precise molecular cascades triggering cisplatin-evoked permanent hearing impairment remain incompletely defined. Therefore, in-depth investigation into the molecular mechanisms of cisplatin-induced ototoxicity and the development of effective prevention strategies represent key scientific issues. Herein, we constructed a chronic cisplatin-exposed animal model and verified prominent pathological features encompassing excessive DNA damage and mitochondrial dysfunction, paralleled by marked downregulation of the DNA repair enzyme MUTYH. Follow-up in vitro assays validated that overexpression of MUTYH significantly alleviated cisplatin-induced ROS accumulation, cell apoptosis, and DNA damage, suggesting that downregulation of MUTYH may be a key molecular event in cisplatin-induced ototoxicity. Notably, exogenous short-chain fatty acid supplementation robustly rescued cisplatin-induced sensory cell loss and hearing loss, concurrent with restored MUTYH abundance. Collectively, our findings reveal that short-chain fatty acids protect cochlear sensory cells from cisplatin-initiated DNA damage via sustaining MUTYH expression, thereby preserving auditory function. As indispensable gut microbial metabolites in humans, short-chain fatty acids supplementation holds promising translational potential as a clinically viable regimen to counteract cisplatin-associated ototoxicity.

PMID 43052245
阅读全文 →
PubMedBMC oral health2026-11-19

Comparative evaluation of the effect of whey protein powder and plant-based protein powder on the microhardness, sorption, and solubility of a nano-hybrid giomer restorative composite: an in vitro study.

Babre Pranjali P, Bohora Aarti A, Patel Pawan P, Sharma Vinay V et al.

Whey and plant protein powders are becoming common additions of people concerned with fitness in their diet. Consumed repeatedly as reconstituted shakes, these products remain in contact with the dentition for extended periods and introduce a chemically heterogeneous mixture of organic acids, fermentable carbohydrates, and bioactive phytochemicals capable of altering the oral environment. Acidic beverages and sports drinks are well documented to compromise resin-based restorative materials, yet comparative data on whey versus plant-based protein powders are lacking. An investigation using an in vitro method of analysis evaluated the effect of the whey protein powder and plant protein powder on the water sorption and solubility of the nano-hybrid giomer restorative composite. Fifty-six disc-shaped Beautifil II a nano-hybrid universal restorative composite incorporating Giomer technology and S-PRG fillers specimens were fabricated and allocated to three immersion groups: WPP, PBP, and distilled water control, with an additional independent baseline group for pre-immersion microhardness assessment. The specimens were exposed to freshly prepared solutions for 10 min at 37 °C daily for 15 days. Vickers microhardness was evaluated using a standardized indentation protocol, while water sorption and water solubility were assessed using a gravimetric mass-difference procedure based on ISO 4049. Specimen-level Wsp and Wsl values were calculated in µg/mm³. Normality was measured by using the Shapiro-Wilk test. The Kruskal-Wallis test followed by Dunn-Bonferroni post-hoc analysis was used for intergroup comparisons of microhardness. Water solubility was compared among the three immersion groups using the Kruskal-Wallis test followed by Bonferroni-adjusted pairwise comparisons, whereas water sorption was reported descriptively because of measurement-resolution limitations. Post-immersion microhardness was highest in the PBP group (86.33 ± 9.54 VHN), followed by WPP (83.93 ± 7.25 VHN), the independent pre-immersion baseline group (80.33 ± 9.46 VHN), and the distilled-water control (80.14 ± 9.48 VHN). After Bonferroni correction, PBP showed significantly higher microhardness than distilled water (adjusted p = 0.041), but its difference from the independent baseline group did not remain significant after adjustment; WPP showed no significant change relative to any comparator. Water solubility differed significantly among the three-immersion media (Kruskal-Wallis, p = 0.001). Mean Wsl was 371.36 ± 87.13 µg/mm³ for PBP, 148.54 ± 108.80 µg/mm³ for WPP, and 137.93 ± 92.85 µg/mm³ for distilled water. PBP demonstrated significantly higher Wsl than WPP (adjusted p = 0.0069) and distilled water (adjusted p = 0.0025), whereas WPP did not differ significantly from distilled water. Mean Wsp was 159.15 ± 150.05 µg/mm³ for PBP, 0.00 ± 115.68 µg/mm³ for WPP, and 26.53 ± 166.61 µg/mm³ for distilled water. Plant-based protein powder produced significantly higher microhardness than distilled water and significantly higher water solubility than both whey protein powder and distilled water, while whey protein powder showed no significant effect on either outcome relative to the neutral control. These preliminary findings are limited to the tested products and experimental conditions. They should not be extrapolated directly to clinical deterioration or used to support specific patient-management recommendations without confirmation from broader laboratory and clinical studies.

PMID 43052983
阅读全文 →
PubMedBMC nutrition2026-11-19

The effects of royal jelly consumption on glycemia indices, lipid profile, and blood pressure in patients with acute ischemic stroke: a randomized, triple-blind trial.

Karimi Elham E, Arab Arman A, Mansouri-Tehrani Hajar-Alsadat HA, Nehls Marilyn S MS et al.

The effects of royal jelly (RJ) on cardiometabolic risk factors in patients with acute ischemic stroke have not been previously reported from this trial. Therefore, we conducted a secondary analysis to investigate the effects of RJ consumption on glycemic indices, lipid profile, and blood pressure. Sixty-four ischemic stroke patients were enrolled in this study and were randomized into the RJ (n = 32) and placebo (n = 32) groups. The trial consisted of a 12-week intervention in which patients consumed either an RJ or a placebo supplement once daily after breakfast. The RJ supplement comprised 30% RJ powder (the equivalent of 1,000 mg of fresh RJ), 53% honey powder, and 17% filler, whereas the placebo comprised 53% honey powder and 47% filler. Post-stroke metabolic profile measures were assessed pre- and post-intervention, including glycemic indices [fasting plasma glucose (FPG), triglyceride glucose index (TyG)], blood pressure measures [systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP)], and lipid profiles [total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C, cholesterol ratio, and triglycerides (TG)]. Following 12 weeks of RJ consumption, MAP [adjusted mean difference (AMD), -4.12 mmHg; 95% CI, -7.95 to -0.29] and FPG (AMD, -13.64 mg/dL; 95% CI, -26.42 to -0.86) were significantly reduced compared to the placebo. Moreover, the TyG index tended to decrease following RJ consumption compared to the control group (AMD, -0.12; 95% CI, -0.29 to 0.04). RJ consumption did not significantly alter other metabolic outcomes in the current study. We found that RJ consumption, in addition to standard treatments, for 12 weeks among patients with acute ischemic stroke may improve metabolic outcomes, including MAP and FPG. Further studies are needed to corroborate these preliminary findings. Iranian Registry of Clinical Trials (IRCT20180818040827N4), registered on October 9, 2021 https//www.irct.ir/trial/59,275.

PMID 43053256
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Geometry-Induced Construction of Sub-Stoichiometric 3D Covalent Organic Frameworks for SO2 Capture.

Chang Jianhong J, Guo Ziang Z, Zhang Jie J, Zhang Zeyue Z et al.

Three-dimensional covalent organic frameworks (3D COFs) have emerged as a rapidly growing class of crystalline porous materials, yet reported structures adhere to the reticular chemistry paradigm of fully connected building blocks. Here, we report a geometry-induced construction strategy that enables the synthesis of sub-stoichiometric 3D COFs─JUC-748, JUC-749, and JUC-750─by deliberately combining building blocks with similar geometries but distinct connectivity. Their structures are determined by continuous rotation electron diffraction and powder X-ray diffraction, revealing that connectivity incompatibility enforces partial condensation and leaves unreacted aldehyde groups periodically arrayed along the pore walls. The frameworks exhibit Brunauer-Emmett-Teller surface areas up to 2836 m2 g-1, and the spatially ordered aldehyde modified pores create a highly favorable adsorption environment for SO2. Remarkably, JUC-748 achieves a SO2 uptake of 16.9 mmol g-1 at 298 K and 1 bar, representing one of the highest values reported for porous organic materials to date. This work establishes geometry-induced construction as a powerful and general strategy for creating intrinsically functionalized 3D COFs with ordered reactive sites, high porosity, and excellent adsorption performance.

PMID 43053452
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-19

Temperature-Dependent Alloy-to-Oxide Transformation in Platinum-Group-Metal High-Entropy-Alloy Nanocrystals.

Lin Jui-Tai JT, Chang Chun-Wei CW, Lin Shang-Cheng SC, Hsu Yu-Chuan YC et al.

Herein, we unravel how temperature governs the oxidation kinetics and alloy-to-oxide phase transformation of platinum-group-metal high-entropy-alloy (HEA, PtPdIrRuRh) nanocrystals in air. By integrating synchrotron high-resolution powder X-ray diffraction (HRPXRD) with Rietveld refinement, scanning transmission electron microscopy (STEM), temperature-programmed oxidation (TPO), X-ray photoelectron spectroscopy (XPS), synchrotron X-ray absorption spectroscopy (XAS), and quantitative compositional analyses, we correlate oxidation-pathway fingerprints with the structural and compositional evolution from room temperature to 900°C. At 300°C, the nanocrystals preserve a single-phase face-centered-cubic (FCC) lattice, with only a thin amorphous oxide overlayer forming, indicating surface-limited oxidation. At 600°C, a rutile-type multicomponent oxide becomes the dominant crystalline phase, accompanied by clear elemental partitioning: Ru, Ir, and Rh are preferentially enriched in the oxygen-rich oxide regions, whereas Pt and Pd are preferentially concentrated in the oxygen-poor residual FCC metallic and/or PdO-related regions. At 900°C, this redistribution becomes more pronounced, producing Pt-rich FCC metallic domains that coexist with Pt-depleted, Rh/Ir/Ru-rich oxide regions. These results show that alloy-to-oxide transformation in compositionally complex nanocrystals couples crystal-structure evolution with elemental partitioning, rather than proceeding through a composition-invariant phase transition, providing a general framework for understanding the oxidative stability and phase segregation of multicomponent nanocrystals under high-temperature conditions.

PMID 43053529
阅读全文 →
PubMedTargeted oncology2026-11-19

Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis.

Matsukawa Akihiro A, Mori Keiichiro K, Yanagisawa Takafumi T, Miyajima Keiichiro K et al.

Contemporary perioperative systemic therapies have improved outcomes in muscle-invasive bladder cancer (MIBC), but comparative evidence between novel strategies is limited. To explore the comparative efficacy and safety of systemic treatment strategies initiated before radical cystectomy. MEDLINE, Embase, Web of Science, and ClinicalTrials.gov were searched on 7 March 2026 for phase III randomized trials. Frequentist random-effects network meta-analysis evaluated overall survival (OS), event-free survival (EFS), and adverse events (AEs). Potential effect modifiers were compared across trials, and sensitivity analyses restricted the network to contemporary gemcitabine/cisplatin (GC)-controlled trials. Evidence certainty was assessed using Confidence in Network Meta-Analysis (CINeMA). CRD420261277299. Eight RCTs were included. Compared with GC, enfortumab vedotin + pembrolizumab (EVP) and durvalumab + GC were associated with improved OS (hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.48-0.89; and HR 0.75; 95% CI 0.60-0.94, respectively) and EFS (HR 0.53; 95% CI 0.41-0.69; and HR 0.68; 95% CI 0.56-0.82, respectively). GC-referenced survival estimates were unchanged in sensitivity analyses. EVP had the highest survival P-scores, but rankings did not establish clinical superiority. The grade ≥ 3 AE estimate for EVP versus GC was (odds ratio; OR) 1.52 (95% CI 1.12-2.07), based on one direct trial. Population, treatment-exposure and outcome-ascertainment differences limited indirect comparisons. This exploratory analysis contextualizes randomized evidence for perioperative EVP and durvalumab + GC. Clinical heterogeneity limits conclusions about comparative superiority or tolerability. Rankings should be interpreted alongside effect estimates and trial-specific evidence.

PMID 43052561
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多cisplatin powder